Stockscreener 앱 받기
2.005
1.88%
0.037
Adagene Inc Adr 주식(ADAG)의 최신 뉴스
Adagene (NASDAQ:ADAG) Earns Buy Rating from Analysts at Guggenheim - Defense World
Adagene (NASDAQ:ADAG) Now Covered by Guggenheim - MarketBeat
Get in on Adagene Inc ADR’s (ADAG) buy-in window today! - Setenews
Can Adagene Inc. Depositary Receipt stock double in next 5 years2025 Price Action Summary & Weekly Consistent Profit Watchlists - newser.com
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives $7.00 Average Target Price from Analysts - Defense World
Adagene (NASDAQ:ADAG) Upgraded at Lifesci Capital - Defense World
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - wahanariau.com
Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development - TipRanks
Adagene Inc. Announces Licensing Agreement with Third Arc Bio to Utilize SAFEbody Technology for CD3 T Cell Engagers - Quiver Quantitative
Adagene Announces Licensing Agreement with Third Arc Bio - GlobeNewswire
Why Adagene Inc. Depositary Receipt stock is in analyst buy zoneTrade Performance Summary & Weekly High Potential Alerts - newser.com
Why Adagene Inc. Depositary Receipt stock is a must watch in 2025Weekly Loss Report & Reliable Trade Execution Plans - newser.com
What’s the recovery path for long term holders of Adagene Inc. Depositary ReceiptExit Point & High Win Rate Trade Alerts - newser.com
Adagene Inc. Depositary Receipt stock daily chart insightsQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Understanding Adagene Inc. Depositary Receipt’s price movement2025 Market Outlook & Community Supported Trade Ideas - newser.com
Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC - Investing.com India
[F-3] Adagene Inc. Foreign Issuer Shelf Registration | ADAG SEC FilingForm F-3 - Stock Titan
Adagene Inc. Initiates Phase 2 Clinical Trial of Muzastotug in Combination with KEYTRUDA for Colorectal Cancer - Quiver Quantitative
Adagene Announces First Patient Dosed in Randomized Dose - GlobeNewswire
Adagene (NASDAQ:ADAG) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Grows By 66.4% - Defense World
CEO Change: Why analysts raise outlook for Adagene Inc. (Common Stock) (978) stockForecast Cut & High Accuracy Swing Entry Alerts - Trung tâm Dự báo KTTV quốc gia
Will Adagene Inc. Depositary Receipt stock recover faster than marketDip Buying & Safe Entry Trade Signal Reports - nchmf.gov.vn
This trade activity should not be overlooked: Adagene Inc ADR (ADAG) - Setenews
Chart based analysis of Adagene Inc. Depositary Receipt trendsBreakout Watch & Advanced Swing Trade Entry Plans - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Up 320.2% in September - Defense World
Adagene Inc. (ADAG) stock price, news, quote and history - Yahoo! Finance UK
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Increase in Short Interest - MarketBeat
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy - Yahoo Finance
How sentiment analysis helps forecast Adagene Inc. Depositary ReceiptMarket Growth Review & AI Driven Price Forecasts - newser.com
Are Medical Stocks Lagging Adagene (ADAG) This Year? - sharewise.com
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Update - MarketBeat
Lucid Capital Markets initiates coverage on Adagene stock with Buy rating - Investing.com India
Adagene Inc. Amends Collaboration Agreement with Exelixis to Advance SAFEbody Technology for Cancer Therapy - Quiver Quantitative
Adagene Expands SAFEbody® Collaboration and License - GlobeNewswire
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - MarketScreener
Breakthrough Cancer Drug Technology: Adagene's 'Invisible' ADC Platform Expands to Third Program - Stock Titan
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 38.1% in August - Defense World
Using economic indicators to assess Adagene Inc. Depositary Receipt potential2025 Historical Comparison & Verified Short-Term Plans - newser.com
Quantitative breakdown of Adagene Inc. Depositary Receipt recent moveProduct Launch & High Return Trade Opportunity Guides - Newser
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Using data tools to time your Adagene Inc. Depositary Receipt exit2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 70.6% - MarketBeat
Adagene’s ADG126 to be Highlighted in Two Presentations at - GlobeNewswire
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - The Manila Times
Adagene Inc. Showcases ADG126 at CSCO Meeting with Promising Results in Advanced MSS Colorectal Cancer - Quiver Quantitative
30% Response Rate: Adagene's Novel Cancer Drug Shows Promise in Hard-to-Treat Colorectal Cancer Trial - Stock Titan
Former YERVOY developer Axel Hoos joins Adagene as advisor - Investing.com
0.83%
0.84%
자본화:
|
볼륨(24시간):